Salkind Gene

SEC source: 0001477932-26-004404 · form4.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 318,750

F1 · shares: Represents restricted stock granted pursuant to the Issuer's 2019 Incentive Stock Plan, as amended, that vests in four equal quarterly installments, with full vesting on July 1, 2027, subject to continued service.

SEC source: 0001683168-26-001025 · ownership.xml · nonDerivative · entry 2

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,161

F2 · price: Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

F3 · ownership.direct: Includes 4,211 shares of common stock that are held as JTWROS with Catherine Salkind.

SEC source: 0001683168-26-001025 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,161

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the exercise price of shares purchased upon exercise of stock options.

F3 · ownership.direct: Includes 4,211 shares of common stock that are held as JTWROS with Catherine Salkind.

SEC source: 0001683168-26-000041 · ownership.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 761,544

Underlying: Common Stock · 250,000 shares

Expires 2030-12-31

F1 · price: Not applicable.

F2 · balance_after: Includes (i) 59,211 shares underlying warrants exercisable at $60 per share, (ii) 2,333 shares underlying options exercisable at $68.48 per share, (iii) 100,000 shares underlying options exercisable at $.20 per share, (iv)100,000 shares underlying a convertible note at $1.00 per share, (v) options to purchase 250,000 shares exercisable at $2.45 per share, and (vi) options to purchase 250,000 exercisable at $1.10 per share.

SEC source: 0001477932-25-008535 · form4.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Trustee

Disclosed balance after: 218,750

F1 · ownership.direct: 50,000 shares were purchased at $2.55 per share on the open market through the Marital Trust GST subject U/W/O Leopold Salkind Gene Salkind, Trustee. These shares are considered indirect ownership of Gene Salkind.

SEC source: 0001477932-25-008466 · form4.xml · nonDerivative · entry 2

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Trustee

Disclosed balance after: 168,750

F1 · ownership.direct: 100,000 shares were purchased at $2.81 per share on the open market through the Marital Trust GST subject U/W/O Leopold Salkind Gene Salkind, Trustee. These shares are considered indirect ownership of Gene Salkind.

SEC source: 0001477932-25-008466 · form4.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 569,470

SEC source: 0001683168-25-007156 · ownership.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 511,544

Underlying: Common Stock · 100,000 shares

Expires 2025-10-17

F2 · security: The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

F3 · price: Not applicable.

F4 · balance_after: Includes (i) 59,211 shares underlying warrants exercisable at $60 per share, (ii) 2,333 shares underlying options exercisable at $68.48 per share, (iii) 100,000 shares underlying options exercisable at $.20 per share, (iv)100,000 shares underlying a convertible note at $1.00 per share and (v) options to purchase 250,000 shares exercisable at $2.45 per share.

SEC source: 0001683168-25-007156 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,668,695

F1 · security: Represents interest paid on a convertible note

F2 · balance_after: The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

SEC source: 0001477932-25-005338 · form4.xml · nonDerivative · entry 3

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 585,370

F3 · shares: Vests quarterly in equal installments over 12 months beginning July 1, 2025.

F4 · shares: The shares of Common Stock reported herein were granted pursuant to the Issuer's Equity Incentive Plan.

SEC source: 0001477932-25-005338 · form4.xml · nonDerivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 435,370

F2 · shares: Vests in full 90 days from July 1, 2025.

F4 · shares: The shares of Common Stock reported herein were granted pursuant to the Issuer's Equity Incentive Plan.

SEC source: 0001477932-25-005338 · form4.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 385,370

F1 · shares: The Reporting Person purchased these shares pursuant to a private placement offering conducted by the Issuer. The Common Stock is being offered pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) of Regulation D promulgated thereunder, and applicable state securities laws.

SEC source: 0001477932-25-002979 · form4.xml · derivative · entry 3

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common · 35,000 shares

Expires 2035-04-17

F2 · derivative.exercise_date: 100% of the options vest on April 17, 2026.

SEC source: 0001477932-25-002979 · form4.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 365,127

F1 · shares: The Reporting Person purchased these shares in a PIPE offering conducted by the Issuer. The shares are restricted securities subject to transfer restrictions under Rule 144 of the Securities Act until such time that they are registered pursuant to a registration statement or become eligible for resale otherwise.

SEC source: 0001683168-25-001392 · ownership.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,950

Underlying: Common Stock · 5,700 shares

Expires not disclosed

F1 · security: On March 4, 2025, the reporting person received a grant of 5,700 stock options, as non-qualified options, under the 2022 equity incentive plan.

F2 · derivative.exercise_price: The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Capital Market on the day of grant.

F2 · price: The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Capital Market on the day of grant.

F3 · derivative.exercise_date: Non-qualified options will vest over 1 year, in four equal installments, with the first 25% vesting on 3/31/2025, the next 25% vesting on 6/30/2025, the next 25% vesting on 9/30/25, and the final 25% vesting on 12/31/25.

F4 · derivative.expiration_date: Expiration date is ten years from the day of grant.

SEC source: 0001477932-25-002979 · form4.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common · 25,000 shares

Expires 2035-01-17

SEC source: 0001683168-25-000023 · ownership.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 411,544

Underlying: Common Stock · 420,000 shares

Expires 2024-12-31

F2 · security: The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

F1 · price: Not applicable.

F3 · balance_after: Includes (i) 59,211 shares underlying warrants exercisable at $60 per share, (ii) 2,333 shares underlying options exercisable at $68.48 per share, (iii) 100,000 shares underlying options exercisable at $.20 per share and (v) options to purchase 250,000 shares exercisable at $2.45 per share.

SEC source: 0001683168-25-000023 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,643,695

F2 · balance_after: The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

SEC source: 0001683168-24-007267 · ownership.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 831,544

Underlying: Common Stock · 250,000 shares

Expires 2029-10-08

F2 · security: The securities listed in Table II are securities owned directly by Dr. Salkind and his wife and by a family trust.

F1 · price: Not applicable.

F3 · balance_after: Includes (i) 420,000 common shares underlying convertible notes, (ii) 59,211 shares underlying warrants exercisable at $60 per share, (iii) 2,333 shares underlying options exercisable at $68.48 per share, (iv) 100,000 shares underlying options exercisable at $.20 per share and (v) options to purchase 250,000 shares exercisable at $2.45 per share.

SEC source: 0001683168-24-005385 · ownership.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 616,201

Underlying: Common Stock · 7,519,730 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust.

F1 · derivative.expiration_date: Not applicable.

SEC source: 0001683168-24-005385 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,223,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: Includes dividend shares issued upon conversion.

F2 · ownership.direct: The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust.

SEC source: 0001683168-24-005963 · salkind_f4.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 581,544

Underlying: Common Stock · 7,519,730 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust.

F1 · derivative.expiration_date: Not applicable.

F4 · balance_after: Includes (i) 420,000 common shares underlying convertible notes, (ii) 59,211 shares underlying warrants exercisable at $60 per share, (iii) 2,333 shares underlying options exercisable at $68.48 per share and (iv) 100,000 shares underlying options exercisable at $.20 per share.

SEC source: 0001683168-24-005963 · salkind_f4.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,223,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: Includes dividend shares issued upon conversion.

F2 · ownership.direct: The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust.

SEC source: 0001683168-24-005116 · ownership.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,135,931

Underlying: Common Stock · 100,000 shares

Expires not disclosed

F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust.

F1 · derivative.expiration_date: Not applicable.

SEC source: 0001683168-24-004578 · ownership.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,035,931

Underlying: Common Stock · 320,000 shares

Expires not disclosed

F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust.

F1 · derivative.expiration_date: Not applicable.

SEC source: 0001683168-24-000161 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 284,056

F1 · balance_after: Includes (i) 95,817 shares of common stock that are held as JTWROS with Catherine Salkind, (ii) 57,268 shares of common stock issuable upon exercise of currently exercisable warrants held as JTWROS with Catherine Salkind, (iii) 101,061 shares of common stock that are issuable upon currently exercisable warrants and (iv) 30,000 shares of common stock that are issuable upon exercise of options that are or will become exercisable in the next 60 days.

SEC source: 0001683168-23-008965 · ownership.xml · derivative · entry 3

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,715,931

Underlying: Common Stock · 100,000 shares

Expires 2028-12-19

F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495.

SEC source: 0001683168-23-008965 · ownership.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,615,931

Underlying: Common Stock · 7,519,730 shares

Expires not disclosed

F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495.

F1 · derivative.expiration_date: Not applicable.

F2 · balance_after: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495.

SEC source: 0001683168-23-008965 · ownership.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,103,990

Underlying: Common Stock · 3,007,789 shares

Expires not disclosed

F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495.

F1 · derivative.expiration_date: Not applicable.

F2 · balance_after: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495.

SEC source: 0001683168-23-007787 · ownership.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,103,990

Underlying: Common Stock · 3,007,890 shares

Expires not disclosed

F3 · security: Salkind and his trust invested an additional $1,200,000 plus converted the $300,000 principal loan plus interest of $3,495 (totaling$1,503,495) into shares of Series G Preferred Stock, convertible at holders option at any time into common stock at an effective price of $.50 per share.

F3 · price: Salkind and his trust invested an additional $1,200,000 plus converted the $300,000 principal loan plus interest of $3,495 (totaling$1,503,495) into shares of Series G Preferred Stock, convertible at holders option at any time into common stock at an effective price of $.50 per share.

F1 · derivative.expiration_date: Not applicable.

SEC source: 0001683168-23-007787 · ownership.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,100

Underlying: Common Stock · 428,571 shares

Expires 2023-11-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Salkind and his trust invested an additional $1,200,000 plus converted the $300,000 principal loan plus interest of $3,495 (totaling$1,503,495) into shares of Series G Preferred Stock, convertible at holders option at any time into common stock at an effective price of $.50 per share.

F2 · balance_after: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. Salkind has the right to convert $300,000 loan into common stock at $.70 per share or into the terms of a financing completed before November 30, 2023.

SEC source: 0001683168-23-007040 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 448,535

F1 · security: The 448,535 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee.

SEC source: 0001683168-23-007786 · ownership.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 524,671

Underlying: Common Stock · 428,571 shares

Expires 2023-11-30

F3 · price: Not applicable.

F2 · balance_after: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. Salkind has the right to convert $300,000 loan into common stock at $.70 per share or into the terms of a financing completed before November 30, 2023.

SEC source: 0001683168-23-007786 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 448,535

F1 · security: The 448,535 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee.

SEC source: 0001683168-23-006169 · ownership.xml · nonDerivative · entry 3

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 4,046

F3 · ownership.nature: Julian R Salkind Trust DTD 10/11/94, for which the Reporting Person is the Trustee.

SEC source: 0001683168-23-006169 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 28,638

F1 · ownership.nature: The Marital Trust GST Subject U/W/O Leopold Salkind, for which the Reporting Person is the trustee.

SEC source: 0001683168-23-002368 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,478,017

F1 · security: The 4,478,017 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee.

SEC source: 0001683168-23-002202 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,092,354

F1 · security: The 3,092,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee.

SEC source: 0001683168-23-000434 · ownership.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F1 · security: On January 27, 2023, the reporting person received a grant of 30,000 stock options, as non-qualified options, under the 2022 equity incentive plan.

F2 · derivative.exercise_price: The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.

F2 · price: The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.

F3 · derivative.exercise_date: Non-qualified options will vest over 1 year, in four equal installments, with the first 25% vesting on 3/31/2023, the next 25% vesting on 6/30/2023, the next 25% vesting on 9/30/23, and the final 25% vesting on 12/31/23.

F4 · derivative.expiration_date: Expiration date is ten years from the day of grant.

SEC source: 0001415889-22-011497 · form4-11172022_091143.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2027-09-30

F1 · derivative.exercise_date: The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months.

F1 · derivative.expiration_date: The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months.

SEC source: 0001683168-22-004784 · ownership.xml · derivative · entry 3

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,441,500

Underlying: Common Stock · 204,000 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

F2 · security: The board of directors of the issuer accepted Dr. Salkind's offer to convert $510,000 of convertible notes at a reduced conversion price of $1.25 per share into 408,000 common shares and warrants to purchase 204,000 shares at an exercise price of $4.00 per share through September 30, 2029.

F3 · price: Not applicable.

F5 · balance_after: 1,441,500 derivative securities include the following: (i) 390,625 common stock purchase warrants exercisable at $4.00 per share through September 2023; (ii) 10-year options to purchase 35,000 shares granted on December 8, 2021; and (iii) warrants to purchase 1,015,875 shares exercisable through September 30, 2029 which were issuable on June 30, 2022 as a result of the note conversion.

SEC source: 0001683168-22-004784 · ownership.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 510,000 shares

Expires 2029-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

F2 · security: The board of directors of the issuer accepted Dr. Salkind's offer to convert $510,000 of convertible notes at a reduced conversion price of $1.25 per share into 408,000 common shares and warrants to purchase 204,000 shares at an exercise price of $4.00 per share through September 30, 2029.

F3 · price: Not applicable.

F4 · balance_after: Left blank intentionally.

SEC source: 0001683168-22-004784 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,992,354

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

SEC source: 0001683168-22-002246 · ownership.xml · derivative · entry 3

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,237,500

Underlying: CommonStock · 684,166 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The 2,484,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

F2 · security: After the close of business on March 29, 2022 and prior to the close of the market on March 30, 2022, the board of directors of the issuer accepted Dr. Salkind's offer to convert $2,052,500 of convertible notes at a reduced conversion price of $1.50 per share into 1,368,333 common shares and warrants to purchase 684,166 shares at an exercise price of $4.00 per share through September 30, 2029. A portion (i.e. $1,542,500) of the note conversion came directly from Dr. Salkind and his wife and a portion (i.e.$510,000) of the note conversion came directly from the trust that Dr. Salkind is the trustee.

F3 · price: Not applicable.

F5 · balance_after: 1,237,500 derivative securities include the following: (i) 127,500 shares underlying $510,000 of debt, convertible at $4.00 per share (excluding 50% warrant coverage - i.e. 63,750 warrants, exercisable at $4.00 per share through September 30, 2029, if and when issued); (ii) 390,625 common stock purchase warrants exercisable at $4.00 per share through September 2023; (iii) 10-year options to purchase 35,000 shares granted on December 8, 2021; and (iv) warrants to purchase 686,166 shares exercisable through September 30, 2029 which were issuable on March 30, 2022 as a result of the note conversion.

SEC source: 0001683168-22-002246 · ownership.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,500

Underlying: Common Stock · 513,125 shares

Expires 2029-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The 2,484,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

F2 · security: After the close of business on March 29, 2022 and prior to the close of the market on March 30, 2022, the board of directors of the issuer accepted Dr. Salkind's offer to convert $2,052,500 of convertible notes at a reduced conversion price of $1.50 per share into 1,368,333 common shares and warrants to purchase 684,166 shares at an exercise price of $4.00 per share through September 30, 2029. A portion (i.e. $1,542,500) of the note conversion came directly from Dr. Salkind and his wife and a portion (i.e.$510,000) of the note conversion came directly from the trust that Dr. Salkind is the trustee.

F3 · price: Not applicable.

F4 · balance_after: The remaining unpaid convertible notes in the principal amount of $510,000 are convertible into 127,500 shares at $4.00 per share, excluding 63,750 warrants issuable upon conversion thereof as described in note 5.

SEC source: 0001683168-22-002246 · ownership.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,484,354

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The 2,484,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.

SEC source: 0001477932-22-001943 · form4.xml · nonDerivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Trustee

Disclosed balance after: 125,000

F1 · balance_after: 125,000 shares were purchased at $4.00 per share in a private transaction through the Marital Trust GST subject U/W/O Leopold Salkind Gene Salkind, Trustee and considered indirect ownership of Gene Salkind

SEC source: 0001683168-21-006258 · ownership.xml · derivative · entry 1

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,422,500

Underlying: Common Stock · 35,000 shares

Expires 2031-12-08

F1 · price: Not applicable.

F2 · balance_after: 1,422,500 derivative securities include the following: (i) 675,000 shares underlying $2.7 million of debt, convertible at $4.00 per share with 50% warrant coverage (i.e. 337,500 warrants, exercisable at $4.00 per share through September 30, 2029, if and when issued); (ii) 375,000 common stock purchase warrants exercisable at $48 per share through September 20, 2023; and (iii) options to purchase 35,000 shares granted on December 8, 2021, which options necessitated this filing.

SEC source: 0001683168-21-004684 · ownership.xml · derivative · entry 3

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,387,500

Underlying: Common Stock · 375,000 shares

Expires 2023-09-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Includes securities or derivative securities heldboth jointly with his spouse and in trust.

F5 · price: None.

SEC source: 0001683168-21-004684 · ownership.xml · derivative · entry 2

Salkind Gene · CIK 0001592481 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,012,500

Underlying: Common stock · 750,000 shares

Expires 2021-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Includes securities or derivative securities heldboth jointly with his spouse and in trust.

F1 · derivative.exercise_price: Not applicable - reporting person converted oneshare of Series C preferred stock into 250 common shares and 250 warrants,exercisable at $48 per share.

F3 · shares: Represents 1,500 shares of Series C preferredstock converted into 375,000 shares of common stock and a like number ofwarrants, exercisable at $48 per share through September 20, 2023.

F5 · price: None.

F4 · derivative.underlying_shares: Includes 375,000 common shares and 375,000warrants, exercisable at $48 per share through September 20, 2023.

F6 · balance_after: Includes 675,000 shares underlying $2.7million of debt convertible at $4 per share, with 50% warrant coverage (i.e. 337,500 warrants). The warrants are exercisable at $4per share through September 30, 2029, if and when, issued.The foregoing numbers exclude interest payable on the debt, which can also beconverted on the same basis.